Online citations, reference lists, and bibliographies.
← Back to Search

Mitigating The Toxic Effects Of Anticancer Immunotherapy

Tara C. Gangadhar, R. Vonderheide
Published 2014 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Advances in our understanding of the regulatory mechanisms of the immune system have led to the development of novel approaches for cancer therapy, including inhibition of immune checkpoints with anti-CTLA-4 and anti-PD-1 antibodies. An increasing number of immunomodulatory treatments are under investigation, and are beginning to show promise in clinical trials. As more-effective therapies become available based on modulation of the immune system in order to trigger or enhance antitumour immune responses, clinicians will need to become familiar with recognizing and controlling the adverse effects arising from immune therapy. This Review describes the toxicity profiles for various anticancer therapies based on the use of agents that block immune checkpoints, immunostimulatory agents, and adoptive T-cell therapy (that is, infusion of modified autologous T cells). The management of patients receiving these treatments presents unique challenges for clinicians. Nevertheless, many of the adverse effects associated with these treatments are reversible and can be managed with supportive care either with or without cessation of therapy. This final point is extremely important given the continued development of new cancer immunotherapies, and the importance of safe and effective use of existing effective FDA-approved agents.
This paper references
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
J. Brahmer (2012)
The blockade of immune checkpoints in cancer immunotherapy
D. Pardoll (2012)
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
A. Eggermont (2008)
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
M. Kalos (2011)
Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.
J. Blansfield (2005)
Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
R. Morgan (2013)
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
J. Kochenderfer (2012)
Durable Complete Responses in Heavily Pretreated Patients with metastatic Melanoma Using T-Cell Transfer Immunotherapy
T. Eberlein (2012)
Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.
S. Mocellin (2010)
Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.
R. Brentjens (2010)
Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
Stephanie G Downey (2007)
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.
C. Louis (2011)
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
S. Gende (2011)
E1608 [abstract
Hodi (2013)
Targeted therapy for metastatic melanoma : from bench to bedside
W. J. Hwu (2010)
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
M. S. Gordon (2009)
Immunostimulatory monoclonal antibodies for cancer therapy
I. Melero (2007)
A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL).
I. Melero (2013)
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
A. Ribas (2013)
Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient.
S. Wilgenhof (2011)
exploiting costimulation and target antigens for active and passive T cell immunotherapy
R. H. Vonderheide (2003)
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
C. Robert (2011)
Endocrine side effects induced by immune checkpoint inhibitors.
S. Corsello (2013)
From Bench To Bedside(第19回)心臓弁膜症と血管新生抑制因子コンドロモデュリン-1
伯野 大彦 (2010)
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
O. Hamid (2013)
Tumor immunotherapy directed at PD-1.
A. Ribas (2012)
Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control
C. Robert (2013)
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
P. Attia (2005)
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
S. Blackburn (2009)
CTLA-4 Blockade with Monoclonal Antibodies in Patients with Metastatic Cancer: Surgical Issues
G. Phan (2008)
surgical issues
G. Q. Phan (2008)
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.
R. Morgan (2010)
case report of an unforeseen adverse event in a phase I clinical trial
Brentjens (2010)
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
S. Grupp (2013)
The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice
R. Gladue (2011)
Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8+ Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy
J. Chacon (2013)
Thyroid dysfunction from antineoplastic agents.
Ole-Petter R Hamnvik (2011)
Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608.
S. Lee (2013)
Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)
M. Sznol (2008)
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.
R. H. Vonderheide (2006)
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
S. Topalian (2012)
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms.
J. Chemnitz (2004)
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.
M. Atkins (1999)
Hepatotoxicity with combination of vemurafenib and ipilimumab.
A. Ribas (2013)
A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma
J. Kirkwood (2004)
Ipilimumab-associated colitis: CT findings.
K. Kim (2013)
pilot clinical trial results
Till (2012)
Strength of PD-1 signaling differentially affects T-cell effector functions
F. Wei (2013)
Agonistic CD40 Antibodies and Cancer Therapy
R. Vonderheide (2013)
The road to recovery: translating PD-1 biology into clinical benefit.
J. Riley (2007)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
G. Phan (2003)
Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12–Associated Toxicity and Interferon-γ Production
J. Leonard (1997)
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications.
A. M. Di Giacomo (2010)
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.
M. Kalos (2013)
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
Kimberly E. Beck (2006)
Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).
H. Kluger (2013)
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.
D. Porter (2011)
Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis.
M. Robinson (2004)
Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells
Brian J. Cameron (2013)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
J. Weber (2009)
CT findings
Kim (2013)
YERVOYTM (ipilimumab): Immune-mediated Adverse Reaction Management Guide [online], https://www.hcp
Bristol-Myers Squibb (2011)
A translational bridge to cancer immunotherapy
R. Vonderheide (2003)
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies.
P. Ascierto (2010)
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.
G. Suntharalingam (2006)
CD 20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD 28 and 4-1 BB domains : pilot clinical trial results
B. Till (2012)
Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4
M. Gordon (2008)
Reply: To PMID 22623561.
Toshihiro Tanaka (2013)
Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM).
O. Hamid (2013)
Management of immune-related adverse events and kinetics of response with ipilimumab.
J. Weber (2012)
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
R. Brentjens (2013)
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.
G. Linette (2013)
T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy
S. Zhong (2013)
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
J. Wilmott (2011)
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.
B. Till (2012)
Nivolumab plus ipilimumab in advanced melanoma.
J. Wolchok (2013)
The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.
J. Wolchok (2008)
Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses.
R. Khattri (1999)
final results of EORTC 18991, a randomised phase III trial
Eggermont (2008)
Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.
K. Margolin (1989)
a new cause of uveitis
Robinson (2004)
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials.
J. Wolchok (2010)
Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy.
J. Kirkwood (2002)
Interferon α adjuvant therapy in patients with high - risk melanoma : a systematic review and meta - analysis
S. Mocellin (2010)
Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
R. Vonderheide (2013)
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
A. Ribas (2005)
Combination checkpoint blockade--taking melanoma immunotherapy to the next level.
James L. Riley (2013)
analysis of toxicity and management guidelines
Margolin (1989)
Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies.
G. Beatty (2013)

This paper is referenced by
Evaluation Of CTLA-4 Blockage Therapy With Metronomic Chemotherapy For The Treatment Of Preclinical Breast Cancer
Karla Parra (2014)
Sorafenib: Experience and Better Management of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis
J. Raoul (2019)
Identification and management of toxicities from immune checkpoint-blocking drugs.
B. Teply (2014)
Targeting immunosuppressive myeloid cells using nanocarriers to improve cancer immunotherapy
M. S. Sasso (2015)
Reducing Toxicity of Immune Therapy Using Aptamer-Targeted Drug Delivery
E. Gilboa (2015)
The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population.
J. Sattar (2019)
A Tumor Mitochondria Vaccine Protects against Experimental Renal Cell Carcinoma
Stefano Pierini (2015)
Lymph-directed immunotherapy - Harnessing endogenous lymphatic distribution pathways for enhanced therapeutic outcomes in cancer.
O. Feeney (2020)
Renal Cell Carcinoma
Ashley K. Losing (2017)
Vaccination against Nonmutated Neoantigens Induced in Recurrent and Future Tumors
G. Garrido (2020)
The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer
José Mª Mazarico Gallego (2020)
Semaphorin 4D in human head and neck cancer tissue and peripheral blood: A dense fibrotic peri-tumoral stromal phenotype
Roshanak Derakhshandeh (2018)
New insights into the anti-PD-L1 and anti-PD-1 reagents in cancer therapy
C. Chen (2016)
PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
K. Soares (2015)
Epithelial Mesenchymal Transition Influence on CTL Activity
Wilfried Engl (2015)
Nuevos avances de tratamiento inmunobiológico en el melanoma avanzado
M. C. Pérez Gago (2017)
Rapid and partial remission of primary lesion but complicated by secondary fibrosis after treatment with nivolumab in a lung squamous carcinoma
L. Ding (2017)
Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth
Karla Parra (2017)
Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC).
P. L. Chia (2016)
Prospects and progress of immunotherapy for bladder cancer
M. Boegemann (2017)
BRAF and MEK inhibitors differentially affect nivolumab-induced T cell activation by modulating the TCR and AKT signaling pathways
Peng Yue (2019)
Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy.
D. R. Wilson (2018)
Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
J. Wang (2019)
Radiomics to predict immunotherapy-induced pneumonitis: proof of concept
R. Colen (2017)
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
C. Xu (2018)
Oncolytic Viral Therapy Using Reovirus.
C. Thirukkumaran (2015)
Targeting the immune system to treat lung cancer: rationale and clinical experience
N. Guibert (2015)
This information is current as against Experimental Renal Cell Carcinoma A Tumor Mitochondria Vaccine Protects
Stefano Pierini (2015)
The Mechanism of Checkpoint Inhibitors in Gynecologic Cancer
Karoutsos Petros (2017)
Immunoengineering with biomaterials for enhanced cancer immunotherapy.
Yu-Qing Xie (2018)
PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges.
J. Lee (2016)
Applying Deep Learning to Discover Highly Functionalized Nucleic Acid Polymers That Bind to Small Molecules
Michael Wornow (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar